Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Respiratory muscle strength and pulmonary function in unvaccinated athletes before and after COVID-19 infection: A prospective cohort study

Özgür Bostancı a, Emre Karaduman a,b, Yunus Çolak b,c, Ali Kerim Yılmaz a, Menderes Kabadayı a, Sait Bilgiç d

a Faculty of Sport Sciences, University of Ondokuz Mayıs, Samsun, Türkiye
b Department of Respiratory Medicine and the Copenhagen General Population Study, Copenhagen University Hospital – Herlev and Gentofte, Copenhagen, Denmark
c Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen DK-2200, Denmark
d Faculty of Medicine, University of Ondokuz Mayıs, Samsun, Türkiye

ARTICLE INFO

Edited by Yu Ru Kou

Keywords:
Athletes
Forced Expiratory Volume
Maximal Respiratory Pressures
Respiratory Function Tests
SARS-CoV-2

ABSTRACT

Purpose: We investigated abnormalities and recovery in respiratory function after COVID-19 infection in an unvaccinated elite athlete population.

Methods: Measurements included maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and peak expiratory flow (PEF).

Results: The most frequent reported symptoms were fatigue with 80% and muscle/joint pain and headache with 50%, whereas only 10% reported dyspnoea and 30% cough. During follow-up, MIP was up to 13% and MEP up to 8% lower following COVID-19 infection. Likewise, FEV1 was up to 2% and FVC up to 5% lower. While MEP and FEV1 rapidly normalised, MIP and FVC still remained abnormal after 52 days of COVID-19 infection, thereby leading to a restrictive ventilatory pattern. PEF seemed unaffected during follow-up.

Conclusions: COVID-19 decreases respiratory function in unvaccinated athletes despite reporting few respiratory symptoms and having mild disease. An initiative aimed at reducing the long-term adverse effects following COVID-19 infection seems warranted, which perhaps may be avoided through vaccination.

1. Introduction

The COVID-19 pandemic has become one of the most critical public health issues that the world is still trying to solve. Although it has been nearly two years since the World Health Organization (WHO) declared the first case with COVID-19 and effective vaccines have been developed (Polack et al., 2020), there are still incidences with severe disease and public events are still prohibited in many countries in order to contain the spread.

Infection with COVID-19 affects the respiratory system and triggers the host’s immune response, which leads to the invasion of hyper-inflammatory neutrophils, monocytes, and macrophages (Chen et al., 2020). This uncontrolled immune response produces the so-called “cytokine storm” with a large release of inflammatory-stimulating cytokines by hyperinflammatory cells (Chen et al., 2020). Recent evidence suggests that the degree of this cytokine storm determines the degree of respiratory functional impairment (Li et al., 2020a; Cascella et al., 2021). Indeed, the clinical presentation in COVID-19 infection has shown substantial variation ranging from asymptomatic carriers to severe disorders such as atypical pneumonia (Jung et al., 2020), hyper-inflammatory phenotype (Lin et al., 2020), respiratory failure (Li et al., 2020b), and acute respiratory distress syndrome (Lin et al., 2020; Xu et al., 2020).

One of the most significant factors affecting exercise performance in professional athletes is respiratory function, and its functioning is mechanically dependent on respiratory muscle capacity. Numerous factors affect the athletes’ respiratory function adversely such as exercise intensity, environmental factors, and acute respiratory disorders. Infection with COVID-19 that specifically targets the respiratory system may cause permanent damage in unvaccinated athletes even in mild disease, thereby affecting exercise performance and put an early end to their professional careers (Hull et al., 2020). Although more than half of patients have recovered from COVID-19 in the general population, little is known how COVID-19 has affected the athlete population (Shah et al., 2021; Smet et al., 2021; Anastasio et al., 2021). In the present study, we investigated abnormalities and recovery in respiratory function after COVID-19 infection in an unvaccinated elite athlete population.

https://doi.org/10.1016/j.resp.2022.103983

Received 4 July 2022; Received in revised form 21 October 2022; Accepted 2 November 2022
Available online 4 November 2022
1569-9048/© 2022 Elsevier B.V. All rights reserved.
COVID-19 infection in an unvaccinated elite athlete population.

2. Methods

2.1. Study population and design

We recruited and prospectively followed a cohort of 25 unvaccinated elite judoists from the Turkish Olympic Preparation Centre in a case-control study design during 52 days in the period between February and April 2021 (Fig. 1). Athletes were unvaccinated before COVID-19 infection, since vaccination was not available for this group of individuals during the pandemic. The respiratory function parameters were periodically followed by the researchers before and after COVID-19 infection. Polymerase Chain Reaction (PCR) test for COVID-19 was performed every 10 days. In total, 11 judoists (44%) were diagnosed with COVID-19. The PCR-positive judoists were included as the case group in the study (n = 11), and the PCR-negative judoists as the control group (n = 14). None of the PCR-positive judoists were admitted to the hospital or died during follow-up and were, thus, representing mild disease as intended. Both case and control groups were isolated in single rooms in the Turkish Olympic Preparation Centre in accordance with the WHO recommendations (WHO, 2020). All athletes did not perform any exercise or training during the 10-day isolation period. Athletes completing the isolation process returned to a low intensity training programme (i.e. judo-specific training) following a negative PCR-testing.

All participants visited the laboratory regularly for respiratory muscle strength and pulmonary function measurements: a measurement before COVID-19 (baseline) and four measurements after infection at day 31, 38, 45, and 52 (post-COVID-19). The athletes were required to avoid strenuous exercise, not to consume caffeinated beverages, and have their last meal at least three hours before each visit. The measurements were made at the same time of the day. Their diet and training programmes were similar because the participants stayed and were followed in the Turkish Olympic Preparation Centre throughout the study period in a controlled environment. The athletes that had a positive PCR test result and manifested any COVID-19 symptoms or fever with > 38.0 °C on measurement days were excluded from the study, corresponding to one case (9%) and four controls (29%); a single participant wished to discontinue for personal reasons. The majority of the discontinued (16%) cases was due to cough, fever, muscle/joint tenderness, and/or fatigue.

The study was approved by the national Turkish Scientific Research Commission established by the Turkish Ministry of Health (project number: T15.40.27) and the Clinical Research Ethics Committee at the University of Ondokuz Mayis (approval number: 2021/126), and was conducted according to the Declaration of Helsinki. All participants provided written informed consent.

Fig. 1. Flowchart. FEV₁ = forced expiratory volume in 1 s. FVC = forced vital capacity. MEP = maximal expiratory pressure. MIP = maximal inspiratory pressure. PEF = peak expiratory flow.


2.2. Respiratory muscle strength and pulmonary function

Respiratory muscle strength was determined using maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP), measured with a MicroRPM (CareFusion Micro Medical, Kent, UK) and assessed in accordance with available guidelines in the field (Laveneziana et al., 2019). All measurements were obtained with the participants in a sitting position with the use of a nose clip. Participants were carefully instructed to exhale to their residual volume and then to inhale to their total lung capacity. Pressure was sustained for at least 1.5 s before MIP and MEP were recorded. At least three measurement were performed before the highest values were selected (McConnell, 2007). Values were expressed as cmH₂O and as percentage of predicted (measured value/predicted value x 100) (Miller and Pincock, 1988) using previously developed prediction equations (Evans and Whitelaw, 2009).

Pulmonary function was determined using forced expiratory volume in 1 s (FEV₁), forced vital capacity (FVC), and peak expiratory flow (PEF), measured with an electronic spirometer (Clement Clarke, Harlow, UK) and assessed in accordance with available guidelines in the field (Graham et al., 2019). Participants were carefully instructed before and during manoeuvre and the procedure was also shown on video. Spirometry was performed with the participants in a seating position with the use of a nose clip. At least three measurement were performed before the highest values were recorded (McConnell, 2007).

2.3. COVID-19 precautions during data collection

The preventive measures for the COVID-19 pandemic within the laboratory and during the tests were applied, as suggested by the national Turkish Society Experts Consensus Report and the European Respiratory Society (ERS) (Gemicioglu et al., 2020; McGowan et al., 2020). Accordingly, COVID-19 infected patients must not be lung function tested for a minimum of 30 days (McGowan et al., 2020). We therefore began lung function measurements 31 days following COVID-19 infection. Surfaces touched by both the participants and researchers were regularly disinfected every 60 min. A sodium hypochlorite solution with a concentration of 0.1–0.5% (5% sodium hypochlorite prepared with 1:10 dilution) was used to eliminate COVID-19 (Kampf et al., 2020). A single-use antiviral and antibacterial filter (low-resistance and with filtration efficacy of 99.9%), mouthpieces, and nasal clips were used for each participant during respiratory muscle strength and pulmonary function measurements. The devices and equipment were sterilised using a disinfector involving 70% isopropyl alcohol before and after each measurement and after each calibration.

2.4. Statistical analysis

SPSS 22.0 for Windows (IBM Inc., Chicago, IL, USA) was used for statistical analyses, and a two-sided P-value < 0.05 was considered as statistical significance. Descriptive data was presented as mean and standard deviation. Normality assumption was evaluated by visual inspection of the histograms (approximating a normal distribution) and applying a Shapiro-Wilk test. Differences in baseline characteristics were assessed using the independent sample t-test analysis. Comparisons between groups over time were determined using mixed repeated-measures analysis of variance (RM ANOVA) with a Bonferroni correction for post hoc analyses. 'Time' for respiratory muscle strength and pulmonary function parameters at baseline and post-COVID-19 (day 31, 38, 45, and 52) and ‘group’ (case and control) were considered as within-subjects and between-subjects factors at five 'time' and two 'group' levels, respectively. As a key assumption, we tested for interaction between time and group. An interaction may suggest that time changes between cases and controls may not be equivalent; however, no substantial violations were detected. The percentage of the mean differences for all respiratory muscle strength and pulmonary function parameters were calculated according to baseline.

3. Results

A total of 20 unvaccinated male elite judoists were included, 10 cases and 10 controls. At baseline examination, controls had slightly higher height, weight, and body mass index (BMI), but there were no overall differences in age or sport experience (Table 1). The three most common reported symptoms in these unvaccinated cases were fatigue with 80%, muscle/joint pain with 50%, and headache with 50%. Only 10% reported dyspnoea and 30% cough.

Respiratory muscle strength as measured with MIP and MEP was reduced in cases subsequently after infection with COVID-19, but gradually increased during 52 days of follow-up (Fig. 2). While MEP normalised between day 45 and 52, MIP was still reduced at day 52. As expected, respiratory muscle strength in controls were unaffected. MIP in cases was 118.6 cmH₂O (corresponding to baseline value) before infection and 105.2 cmH₂O (corresponding to ~13% from baseline value) at day 31, 107.7 cmH₂O (~10%) at day 38, 107.8 cmH₂O (~10%) at day 45, and 113.6 cmH₂O (~4%) at day 52 after infection (p = 0.003) (Fig. 2). MEP in cases was 176.2 cmH₂O (corresponding to baseline value) before infection and 163 cmH₂O (corresponding to ~8% from baseline value) at day 31, 165.4 cmH₂O (~6%) at day 38, 170.6 cmH₂O (~3%) at day 45, and 176.9 cmH₂O (0%) at day 52 after infection (p = <0.001) (Fig. 2). Corresponding value for MIP as percentage of predicted was 105.4% (baseline), 93.5%, 95.7%, 95.8% and 100.9%, and for MEP as percentage of predicted was 110.9% (baseline), 102.6%, 104.1%, 107.4% and 111.3%, respectively.

Pulmonary function as measured with FEV₁ and FVC was also reduced in cases subsequently after infection with COVID-19, and gradually increased during 52 days of follow-up (Fig. 3). Interestingly, FVC was much more reduced than FEV₁ and as a consequence an increment in FEV₁/FVC could be observed. While FEV₁ normalised already between day 31 and 38, FVC was still reduced at day 52. In contrast, PEF seemed unaffected during the whole 52 days of follow-up period. As expected, pulmonary function in controls were unaffected. FEV₁ in cases was 4.06 L (corresponding to baseline value) before infection and 3.98 L (corresponding to ~2% from baseline value) at day 31, 4.08 L (1%) at day 38, 4.16 L (2%) at day 45, and 4.18 L (3%) at day 52 after infection (p = <0.001). Corresponding values for FVC in cases was 4.86 L (baseline), 4.65 L (~4%), 4.59 L (~5%), 4.72 L (~3%) and 4.76 L (~2%), respectively (p = 0.010) (Fig. 3).

4. Discussion

In the present study, we investigated abnormalities and recovery in respiratory function after COVID-19 infection in an unvaccinated elite athlete population. We found that COVID-19 infection decreases respiratory muscle strength and pulmonary function in unvaccinated athletes despite reporting few respiratory symptoms and having mild disease. While MEP and FEV₁ began to rapidly normalise after 31 days and

| Table 1 | Baseline characteristics of case and control judoists from the Turkish Olympic Preparation Centre. |
|---------|--------------------------------------------------------------------------------------------------|
| Age, years | Case (n = 10) | Control (n = 10) | Total (n = 20) |
| 18.2 ± 0.6 | 18.8 ± 1.5 | 18.5 ± 1.1 |
| Height, cm | 175.8 ± 6.9 | 180.5 ± 9 | 178.2 ± 8.2 |
| Weight, kg | 74.3 ± 15.5 | 80.2 ± 15.1 | 77.3 ± 15.2 |
| BMI, kg/m² | 24 ± 4.2 | 25.1 ± 3.7 | 24.5 ± 3.9 |
| Sport experience, years | 7.4 ± 1.7 | 7.5 ± 2.1 | 7.5 ± 1.8 |
| Weight class, kg | 69.5 ± 12.5 | 75.1 ± 12.4 | 72.3 ± 12.5 |

Data are presented as mean ± standard deviation. No differences were observed between cases and controls. All comparisons had P-values ≥ 0.05. BMI = body mass index.
et al., 2020). Moderate exercise has been shown to boost the immune system response (Assaf et al., 2020; Corse et al., 2021). It is important to note that symptoms at the onset or after COVID-19 infection vary widely in the general population and seem among others to be age-related structural differences may affect the altered immune responses to SARS-CoV-2 and thus the severity of disease or symptoms (Manilla-Galindo et al., 2021; Bajaj et al., 2021). However, it is also important to note that symptoms at the onset or after COVID-19 infection vary widely in the general population and seems among others to be affected by how the immune system responds (Assaf et al., 2020; Corse et al., 2020). Moderate exercise has been shown to boost the immune system, whereas strenuous exercise seems to suppress it and increases inflammatory response during training sessions (Rahmati-Ahmadabad and Hosseini, 2020; Simpson et al., 2020). Impaired immune system during strenuous exercise may have increased the amount of viral load.

Fig. 2. Respiratory muscle strength in case and control judoists before and 31, 38, 45, and 52 days after COVID-19 infection. Percentages indicate change from baseline value. MIP=maximal inspiratory pressure, MEP=maximal expiratory pressure.

recovered almost fully during 52 days following a COVID-19 infection, MIP and FVC were still affected. These findings suggest that athletes may need a longer recovery time before being able to return to training and competition following a COVID-19 infection, which perhaps may be avoided through vaccination.

Despite significant reductions in respiratory capacity already observed in the early days following COVID-19 infection, only 10% of the unvaccinated athletes reported dyspnoea and 30% cough. Instead, the most typical symptoms were fatigue (80%), headache (50%), and muscle/joint pain (50%) suggesting mild disease, which at first glance seems different from the symptoms reported in the general population (Rodriguez-Morales et al., 2020). In our cohort, age and physical activity may be the most important factors contributing to the mild symptoms encountered by the participants. It has been reported that age-related structural differences may affect the altered immune responses to SARS-CoV-2 and thus the severity of disease or symptoms (Manilla-Galindo et al., 2021; Bajaj et al., 2021). However, it is also important to note that symptoms at the onset or after COVID-19 infection vary widely in the general population and seems among others to be affected by how the immune system responds (Assaf et al., 2020; Corse et al., 2020). Moderate exercise has been shown to boost the immune system, whereas strenuous exercise seems to suppress it and increases inflammatory response during training sessions (Rahmati-Ahmadabad and Hosseini, 2020; Simpson et al., 2020). Impaired immune system during strenuous exercise may have increased the amount of viral load in these unvaccinated athletes infected with COVID-19 and may also explain some of the differences in symptoms when compared to the general population (Liu et al., 2020). Interestingly, a study of 48,440 adult patients with COVID-19 reported that regular physical activity is less likely to be hospitalised, admitted to intensive care, and die from COVID-19 than those reporting a sedentary lifestyle (Salills et al., 2021). Furthermore, physically active lifestyle seems to minimise or protect against the incidence, duration, or severity of COVID-19 (de Souza et al., 2021; Zbinden-Foncea et al., 2020; Salgado-Aranda et al., 2021). Physical activity may affect susceptibility to infection by modifying immunological response and cellular immunity (Amatriain-Fernandez et al., 2020; Nieman and Wentz, 2019; da Silveira et al., 2021). Different mechanisms (aerobic capacity, regulated C-reactive protein concentration, immunoglobulin level) may be in play in relation to moderate and strenuous exercise.

To our knowledge, the impact of COVID-19 infection on respiratory muscles has not previously been followed periodically in unvaccinated athletes, however, small studies have demonstrated respiratory muscle weakness in the post-COVID-19 chronic period. Since respiratory muscles drive alveolar ventilation, and their weakness may result in imbalances in the demands required for ventilation, it is an important issue to clarify as it may affect the performance of the athletes despite mild disease, not only temporarily but also in the long term. Interestingly, MIP normalised more slowly than MEP and did not recover completely following COVID-19 infection in the present study with up to 52 days follow-up. This may to some part be explained by muscle deconditioning and/or diaphragmatic myopathy (Anastasio et al., 2021; Shi et al., 2021). Assuming that inspiration is an active movement (muscle contraction) compared to expiration, inspiratory structures with muscle deconditioning and/or myopathy may take longer time to recover. A post mortem study revealed that angiotensin-converting enzyme 2 is expressed in the human diaphragm, and viral infiltration of SARS-CoV-2 was present in the diaphragm myofibers of patients infected with COVID-19 (Shi et al., 2021). In the same study, there was also an increased expression of genes involved in fibrosis as well as histologically verified development of fibrosis in the diaphragm (Shi et al., 2021). This myopathic phenotype may lead to reductions in inspiratory muscle force-generating capacity of the diaphragm that could trigger respiratory dysfunction through various mechanisms, perhaps also be responsible for the deterioration in pulmonary function. While FEV1 normalised rapidly between days 31 and 38, FVC was still affected at day 52, thereby leading to a slightly restrictive ventilatory pattern. A systematic review has suggested that a restrictive ventilatory pattern may be more common following a COVID-19 infection than an obstructive ventilatory pattern (Boutou et al., 2021). COVID-19 infected patients often have signs of acute exudative lesions with diffuse alveolar damage and fibrotic changes, which may lead to a decrease in pulmonary compliance and a restrictive ventilatory pattern (Carsana et al., 2020; Yao et al., 2020).

Previous studies have demonstrated poor respiratory outcomes in unvaccinated patients with COVID-19 (Mo et al., 2020; Zhao et al., 2020). In a cohort of 57 hospitalised patients with COVID-19, more than half showed impairment in respiratory muscle strength during early convalescence phase (Huang et al., 2020). A prospective cohort study of 55 survivors with Severe Acute Respiratory Syndrome (SARS) showed permanently abnormal MEP values, and MIP values notably decreased over a duration of 24 months (Ngai et al., 2010). Celik et al. found inspiratory and expiratory muscle-weakening in female volleyball players in the chronic period after COVID-19 infection (Celik et al., 2021). In an unvaccinated athlete population, we now demonstrate that MEP recovers rapidly, whereas MIP still seems to be reduced after 52 days of COVID-19 infection.

A few reports retrospectively evaluated the pulmonary function of unvaccinated COVID-19 survivors a month after hospital discharge, which showed that some patients continued to have significant reductions in FEV1 and FVC (Mo et al., 2020; Huang et al., 2020).
Fumagalli et al. demonstrated that FEV\textsubscript{1} and FEV\textsubscript{1}/FVC recovered to normal, whereas FVC was still low 6 weeks after hospital discharge in 13 patients with COVID-19 (Fumagalli et al., 2021). However, another study showed that anomalies in FEV\textsubscript{1} and FVC continued for 11% and diffusing capacity for 16% at follow-up 3 months after hospital discharge (Zhao et al., 2020). In contrast to all other studies, Frija-Masson et al. found that FEV\textsubscript{1} and FVC were normal for 12 unvaccinated non-critical patients only 1 month after symptom onset (Frija-Masson et al., 2020). In addition, previous studies have revealed that pulmonary function may be normalised in the long term 3–12 months after in SARS survivors (Ng et al., 2004; Ong et al., 2005); however, decreased diffusing capacity may still persist in up to 45% (Ngai et al., 2010; Su et al., 2007). In another study, abnormal pulmonary function continued for nearly up to ten weeks in more than 50% of unvaccinated COVID-19 survivors (Shah et al., 2021; Smet et al., 2021). In a small cohort of unvaccinated soccer players, post-infection (at least 15 days after clinical resolution) FVC, FEV\textsubscript{1}, and PEF were decreased (Gervasi et al., 2021). In an unvaccinated athlete population, we now demonstrate that FEV\textsubscript{1} recovers rapidly, whereas FVC still seems to be reduced after 52 days of COVID-19 infection leading to a restrictive ventilatory pattern. Both the case and control groups did not perform any exercise or training during the 10-day isolation period, but they returned to a low-intensity training programme immediately after the isolation period. Moreover, the athletes continued their normal-intensity training programmes after the low-intensity training period (approximately 7 days after). We think that the decreased activity level due to infection cannot affect the respiratory capacity, since the cases shared same training/detraining conditions as the controls, and the controls did not experience decrease in their respiratory capacity as the cases (Figs. 2 and 3). These results show us that it may be due to the COVID-19-specific infection rather than the decreased levels of activity. More research is required to identify mechanisms for rapid recovery and permanent damage related to respiratory muscle strength and pulmonary following a COVID-19 infection.

Strengths of the present study include a professional unvaccinated athlete population at an Olympic-level with important respiratory physiology measurements before and after a COVID-19 infection in a well-controlled environment. Furthermore, it is also a strength to have repeated measurements. This study has several limitations. Firstly, we were not able to investigate the relationship between respiratory abnormalities and performance, since we avoided complex measurements such as aerobic capacity and gas analysis due to contamination risk during the COVID-19 pandemic and precautions. Secondly, we were unable to establish a vaccinated group within the same population because vaccination was not available at the time of data collection. Thirdly, we had a relatively small sample size, which may affect generalisability to other athlete populations. However, our findings may still contribute to understand the changes in respiratory muscle strength and pulmonary function in professional unvaccinated athlete population during and after COVID-19 infection. Finally, we were unable to capture a full recovery in all participants, and it would be preferable to have a longer follow-up time, which is not possible, and this could therefore be regarded as a limitation.

5. Conclusion

In conclusion, we found that COVID-19 decreases respiratory muscle strength and pulmonary function in unvaccinated athletes despite reporting few respiratory symptoms and having mild disease. Athletes

**Fig. 3.** Pulmonary function in case and control judoists before and 31, 38, 45, and 52 days after COVID-19 infection. Percentages indicate change from baseline value. FEV\textsubscript{1} = forced expiratory volume in 1 s. FVC = forced vital capacity. PEF = peak expiratory flow.
may need a longer recovery time before being able to return to training and competition. An initiative aimed at reducing the long-term adverse effects following COVID-19 infection seems warranted, which perhaps may be avoided through vaccination.

**Funding**

This study was funded by University of Ondokuz Mayıs. The funder had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

**Contributors**

ÖB and EK had full access to all data in the study and had final responsibility for the decision to submit. ÖB and EK contributed to the study concept and design. ÖB, EK, and AKY collected, analysed, or interpreted the data. ÖB and AKY wrote the draft manuscript. YÇ, MK, and SB revised the manuscript for important intellectual content. All authors have read and approved the final version of the manuscript.

**Disclosure statement**

YÇ reports personal fees from Boehringer-Ingelheim, AstraZeneca, and Sanofi Genzyme outside the submitted work. ÖB, EK, AKY, MK, and SB have nothing to disclose. The views expressed are those of the authors.

**Data Availability**

No data was used for the research described in the article.

**Acknowledgements**

We thank our athletes and their coaches for helping us to reveal the effects of COVID-19 infection on athletes.

**References**

Amatriain-Fernández, S., Gronwall, T., Murillo-Rodríguez, E., Imperatori, C., Solano, A. F., Latini, A., et al., 2020. Physical exercise potentials against viral diseases like COVID-19 in the elderly. Front Med (Lausanne) 7, 379. https://doi.org/10.3389/fmed.2020.00379.

Anastasio, F., Barbuto, S., Scarnecchia, E., Cosma, P., Fugagnoli, A., Rossi, G., et al., 2021. Extended cardiopulmonary screening useful in athletes with previous asymptomatic or mild SARS-CoV-2 infection. Br. J. Sports Med 55 (1), 54–61. https://doi.org/10.1136/bjsports-2020-102789.

Graham, B.L., Steenbruggen, I., Miller, M.R., Barjaktarevic, I.Z., Cooper, B.G., Hall, G.L., et al., 2019. Standardization of spirometry 2019 update: an official american thoracic society and european respiratory society technical statement. Am. J. Respir. Crit. Care Med 200 (8), e70–e88. https://doi.org/10.1164/rccm.201908-1590ST.

Huang, Y., Sun, C., Wang, S., Liu, Y., Yuan, Y., Yang, L., et al., 2020. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect. Dis. 20 (10), 1135–1141. https://doi.org/10.1016/S1473-3099(20)30175-2.

Liu, Y., Yao, L., Wang, L., Wu, X., Pan, Y., Zhou, X., et al., 2020. Functional characteristics of patients with SARS-CoV-2 pneumonia at 30days post-infection. Eur. Respir. J. 56 (2), 2001754. https://doi.org/10.1183/13993003.02465-2020.

McConnell, A., 2007. Lung and respiratory muscle function. In: Winter, E.M., Jones, A. (Eds.), The British Association of Sport and Exercise Sciences Guide (1st ed.). Routledge.

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect. Dis. 20 (10), 1135–1140. https://doi.org/10.1016/S1473-3099(20)30434-5.

Casalda, M., Bajnok, M., Alem, A., Dulehun, S.C., Di Napoli, R., 2021. Features, evaluation, and treatment of coronavirus (COVID-19). In: StatPearls 2021. www.statpearls.com.

O., Saryal, S., 2020. Coronavirus disease 2019 on pulmonary function in early convalescence phase. Eur. Respir. J. 55 (6), 2001659. https://doi.org/10.1002/eurj.202001659.

Ng, C.K., Chan, J.W., Kwan, T.L., To, T.S., Chan, Y.H., Ng, F.Y., 2004. Six month evaluation, and treatment of coronavirus (COVID-19). In: StatPearls 2021. www.statpearls.com.

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect. Dis. 20 (10), 1135–1141. https://doi.org/10.1016/S1473-3099(20)30434-5.

Corse, T., Dayan, L., Kersten, S., Battlaglia, F., Terlecky, S.R., Han, Z., 2020. Clinical outcomes of COVID-19 patients with pre-existing, complicated immune systems: a review of case reports. Int. J. Med Sci. 17 (8), 2974–2986. https://doi.org/10.7150/ijms.50537.

da Silveira, M.P., da Silva Fagundes, K.K., Bizut, M.R., Starck, É., Rossi, R.C., de Resende, E., Silva, D.T., 2021. Physical exercise as a tool to help the immune system against COVID-19: an integrative review of the current literature. Clin. Exp. Med. 21 (1), 15–28. https://doi.org/10.1023/b:pmso.0000060-50360.

Evans, J.A., Whitehall, W.A., 2009. The assessment of maximal respiratory mouth pressures in adults. Respir. Care 54 (10), 1349–1359.

Frijia-Masson, J., Dehpy, M.R., Gilbert, M., Lencure, F.X., Travert, F., Borie, R., et al., 2020. Functional characteristics of patients with SARS-CoV-2 pneumonia at 30days post-infection. Eur. Respir. J. 56 (2), 2001754. https://doi.org/10.1183/13993003.02465-2020.
Nieman, D.C., Wentz, L.M., 2019. The compelling link between physical activity and the body’s defense system. J. Sport Health Sci. 8 (3), 201–217. https://doi.org/10.1016/j.jshs.2018.09.005.

Ong, K.C., Lee, L.S., Kaw, G., Kwok, S.K., Leow, M.K., et al., 2005. Pulmonary function and health status in survivors of severe acute respiratory syndrome. Chest 128 (3), 1393–1400. https://doi.org/10.1378/chest.128.3.1392.

Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Gruber, W.C., 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med 383, 2603–2615. https://doi.org/10.1056/NEJMa2034577.

Rahmati-Ahmadabad, S., Hosseini, F., 2020. Exercise against SARS-CoV-2 (COVID-19): does workout intensity matter? (A mini review of some indirect evidence related to obesity. Obes. Med 19, 100245. https://doi.org/10.1016/j.obmed.2020.100245.

Rodriguez-Morales, A.J., Cardona-Ospina, J.A., Gutierrez-Ocampo, E., Villamizar-Peña, R., Holguin-Rivera, Y., Escalera-Antezana, J.P., et al., 2020. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect. Dis. 34, 101623 https://doi.org/10.1016/j.tmaid.2020.101623.

Salgado-Aranda, R., Pérez-Castellano, N., Núñez-Gil, I., Oreacon, A.J., Torres-Esquibel, N., Flores-Soler, J., et al., 2021. Influence of baseline physical activity as a modifying factor on COVID-19 mortality: a single-center, retrospective study. Infect. Dis. Ther. 10 (2), 801–814. https://doi.org/10.1007/s40121-021-00418-6.

Sallis, R., Young, D.R., Tartof, S.Y., Sallis, J.F., Sall, J., Li, Q., et al., 2021. Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients. Br. J. Sports Med 55 (19), 1099–1105. https://doi.org/10.1136/bjsports-2021-104080.

Shah, A.S., Wong, A.W., Hague, C.J., Murphy, D.T., Johnston, J.C., Ryerson, C.J., et al., 2021. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax 76 (4), 402–404. https://doi.org/10.1136/thoraxjnl-2020-214309.

Shi, Z., de Vries, H.J., Vlaar, A.P.J., van der Horven, J., Boon, R.A., Heunks, L.M.A., et al., 2021. Diaphragm pathology in critically ill patients with COVID-19 and postmortem findings from 3 medical centers. JAMA Intern Med 181 (1), 122–124. https://doi.org/10.1001/jama.2020.0278.

Simpson, R.J., Campbell, J.P., Gleeson, M., Krüger, K., Nieman, D.C., Pyne, D.B., et al., 2020. Can exercise affect immune function to increase susceptibility to infection? Exerc Immunol. Rev. 26, 8–22.

Smith, J., Stylemans, D., Hanon, S., Ilonen, B., Verbanck, S., Vanderhelst, E., 2021. Clinical status and lung function 10 weeks after severe SARS-CoV-2 infection. Respir. Med 176, 106276. https://doi.org/10.1016/j.rmed.2020.106276.

Smet, J., Stylemans, D., Ilonen, S., Hanon, B., Verbanck, S., Vanderhelst, E., 2021. Association of physical activity levels and the prevalence of COVID-19-associated hospitalization. J. Sci. Med Sport 24 (9), 913–918. https://doi.org/10.1016/j.jsams.2021.05.012.

Su, M.C., Hsieh, Y.T., Wang, Y.H., Lin, A.S., Chung, Y.H., Lin, M.C., 2007. Exercise capacity and pulmonary function in hospital workers recovered from severe acute respiratory syndrome. Respiration 74 (5), 511–516. https://doi.org/10.1159/000095673.

WHO (2020) Clinical management of severe acute respiratory infection when COVID-19 disease is suspected: interim guidance. www.who.int/publications/i/item/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. (Accessed 18 March 2021).

Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., et al., 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med 8 (4), 420–422. https://doi.org/10.1016/S2213-2600(20)30076-3.

Zhao, Y.M., Shang, Y.M., Song, W.B., Li, Q.Q., Xie, H., Xu, Q.F., et al., 2020. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine 25, 100463. https://doi.org/10.1016/j.eclinm.2020.100463.